• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Clinical Data

Blue background with pill pattern with the words The Top Line
Podcast

What were the biggest clinical trial flops of 2025?

On this episode of "The Top Line," Fierce Biotech's James Waldron and Fierce Pharma's Fraiser Kansteiner discuss the clinical trial failures that stood out in 2025.
Ayla Ellison , James Waldron , Fraiser Kansteiner Feb 13, 2026 11:47am
IV drug delivery

Lundbeck’s preventative migraine IV sees success in ph. 2

Feb 12, 2026 1:25pm
business targets illustration

BridgeBio preps approval push for dwarfism drug after ph. 3 win

Feb 12, 2026 7:30am
salmon river fish jump upstream katmai alaska

Upstream posts Tezspire-like asthma efficacy in phase 2

Feb 11, 2026 7:24am
Completing steps towards success checkmark on cubes symbolizing progress

Nektar eczema asset 'checked all of the boxes' in phase 2

Feb 10, 2026 10:55am
Graphic image of an arrow nailing the bullseye of a target

Evommune's Dupixent-like eczema data drive 75% stock rally

Feb 10, 2026 9:31am
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings